Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)

Condition(s) studied

Investigational drug(s) / intervention(s)

a high dose of statin/ezetimib: In randomization, 100 patients will proceed with Rosuvastatin/Ezetimib 20/10 mg and 100 patients will proceed with Atovastatin/Ezetimib 40/10 mg. A new generation of drug elution stents can be inserted and later registered, and if the patient agrees to participate in the study, they are randomly assigned after stent implantation.

Study summary

the investigators would like to compare the differences between roschvastin and atovastatin in patients who require high-dose statin/ejetimib to undergo a new generation of drug elution stent implantation for cardiovascular disease and maintain LDL cholesterol below 55 mg/dL.

Eligibility

Primary outcome measure(s)

• Percentage of statins changed — 12 months
  Percentage of statins changed to discontinuation or intolerance (muscle pain, muscle efficiency, elevated liver level, etc.) within a year
• Rate at which LDL cholesterol remains below 55 mg/dL — 12 months
  Rate at which LDL cholesterol remains below 55 mg/dL in all 1-year blood tests

Trial sites (1)

More Yonsei University trials in South Korea

Other trials for the same condition